According to the company, this move represents a new stage of efficient and innovative production of medicines that treat serious diseases.
Biologic medicines are developed in living cells and the new Tuas facility has multiple technologies to allow greater speed, productivity and flexibility in commercial-scale manufacturing. The facility was constructed in less than two years and was completed in half the time required for conventional biomanufacturing plants. It utilises single-use bioreactors, disposable plastic containers, continuous purification processing and real-time quality analysis.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia